Business
Roxane Acquisition Close
Roxane Acquisition Close.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 4936Q Hikma Pharmaceuticals Plc 29 February 2016 \n\nClosing of Acquisition and issue of Consideration Shares\nLondon, 29 February 2016 - Hikma Pharmaceuticals PLC (\"Hikma\" or the \"Company\") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, announced on 28 July 2015 that it had agreed terms to acquire Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc. from Boehringer Ingelheim Corporation (the \"Acquisition\").\nThe Company is pleased to announce that the Acquisition closed today, following satisfaction of all necessary conditions.\nIn accordance with the terms of the Acquisition, the Company issued 40,000,000 new fully paid ordinary shares to Boehringer Ingelheim Corporation (the \"Consideration Shares\"), which will represent approximately 16.71 per cent. of the Company's share capital immediately following closing of the Acquisition and Admission (as defined below).\nApplications have been made for the Consideration Shares to be admitted to the premium segment of the Official List of the UKLA and to be admitted to trading on the London Stock Exchange's main market for listed securities (\"Admission\"). It is currently anticipated that Admission will occur at 7.00a.m. tomorrow.\nFurther to the announcement on 24 December 2015 noting that Dr. Gann would be appointed as a non-executive director of Hikma on closing of the Acquisition, the appointment is effective from the date of this announcement.\nFor further details please contact:\nHikma Pharmaceuticals PLC \nSusan Ringdal, VP Corporate Strategy and Investor Relations \n+44 (0)20 7399 2760/+44 7776 477050\n\nZeena Murad, Investor Relations Manager\n+44 (0) 20 7399 2768/+44 7771 665277 \nFTI ConsultingBen Atwell/ Matthew Cole \n+44 (0)20 3727 1000 \nAbout HikmaHikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: \"Branded\", \"Injectables\" and \"Generics\", based principally in the Middle East and North Africa (\"MENA\"), where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of US$1,489 million and profit attributable to shareholders ...